Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Free Zinc as a Predictive Marker for COVID-19 Mortality Risk.
Maares M, Hackler J, Haupt A, Heller RA, Bachmann M, Diegmann J, Moghaddam A, Schomburg L, Haase H. Maares M, et al. Among authors: haupt a. Nutrients. 2022 Mar 28;14(7):1407. doi: 10.3390/nu14071407. Nutrients. 2022. PMID: 35406020 Free PMC article.
A fluorometric assay to determine labile copper(II) ions in serum.
Maares M, Haupt A, Schüßler C, Kulike-Koczula M, Hackler J, Keil C, Mohr I, Schomburg L, Süssmuth RD, Zischka H, Merle U, Haase H. Maares M, et al. Among authors: haupt a. Sci Rep. 2023 Aug 7;13(1):12807. doi: 10.1038/s41598-023-39841-9. Sci Rep. 2023. PMID: 37550465 Free PMC article.
Author Correction: A fluorometric assay to determine labile copper(II) ions in serum.
Maares M, Haupt A, Schüßler C, Kulike-Koczula M, Hackler J, Keil C, Mohr I, Schomburg L, Süssmuth RD, Zischka H, Merle U, Haase H. Maares M, et al. Among authors: haupt a. Sci Rep. 2024 Apr 17;14(1):8859. doi: 10.1038/s41598-024-59455-z. Sci Rep. 2024. PMID: 38632369 Free PMC article. No abstract available.
Automated human induced pluripotent stem cell culture and sample preparation for 3D live-cell microscopy.
Gregor BW, Coston ME, Adams EM, Arakaki J, Borensztejn A, Do TP, Fuqua MA, Haupt A, Hendershott MC, Leung W, Mueller IA, Nath A, Nelson AM, Rafelski SM, Sanchez EE, Swain-Bowden MJ, Tang WJ, Thirstrup DJ, Wiegraebe W, Whitney BP, Yan C, Gunawardane RN, Gaudreault N. Gregor BW, et al. Among authors: haupt a. Nat Protoc. 2024 Feb;19(2):565-594. doi: 10.1038/s41596-023-00912-w. Epub 2023 Dec 12. Nat Protoc. 2024. PMID: 38087082 Review.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Rosenstock J, et al. Among authors: haupt a. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385280 Clinical Trial.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Jastreboff AM, et al. Among authors: haupt a. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. N Engl J Med. 2023. PMID: 37366315 Clinical Trial.
180 results